Stocktoria
Tvardi Therapeutics, Inc. TVRD
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2014-01-31
Tvardi Therapeutics, Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $7.1M | $21.0M | $41.9M | $23.0M | $135.1M | $19.9M | $13.5M | $911,000 | $86,000 |
| R&D expense | $18.0M | $23.6M | $108.5M | $91.9M | $82.7M | $107.9M | $113.8M | $75.5M | $48.5M | $49.3M |
| Operating income | -$26.7M | -$28.1M | -$121.5M | -$87.5M | -$89.1M | $5.4M | -$111.7M | -$77.4M | -$59.5M | -$58.4M |
| Income tax | $0 | $0 | $0 | $0 | $0 | -$691,000 | -$816,000 | -$389,000 | -$204,000 | -$468,000 |
| Net income | -$18.2M | -$29.4M | -$118.5M | -$85.5M | -$88.4M | $8.4M | -$106.4M | -$74.0M | -$58.1M | -$57.3M |
| EPS (diluted) | $-3.26 | $-11.42 | $-26.26 | $-19.12 | $-1.74 | $0.18 | $-2.49 | $-2.06 | — | — |
| Operating cash flow | -$23.5M | -$18.3M | -$92.1M | -$78.7M | -$60.1M | -$5.5M | -$109.2M | -$22.3M | -$54.8M | -$47.4M |
| Free cash flow | — | -$19.4M | -$94.5M | -$78.8M | -$60.1M | -$5.8M | -$109.2M | -$22.4M | -$54.9M | -$48.1M |
| Cash & equivalents | $20.7M | $31.6M | $51.8M | $63.7M | $13.5M | $31.7M | $18.3M | $15.1M | $9.4M | $12.1M |
| Inventory | — | $900,000 | $2.8M | $2.4M | $2.6M | — | — | — | — | — |
| Total assets | $32.1M | $35.2M | $125.8M | $182.2M | $247.1M | $271.2M | $233.0M | $190.8M | $97.0M | $63.8M |
| Total liabilities | $11.1M | $40.8M | $68.8M | $23.5M | — | — | — | — | — | — |
| Shareholders' equity | $20.9M | -$91.1M | -$62.1M | $158.8M | $227.5M | $249.0M | $186.7M | $133.6M | $86.8M | $50.7M |
Growth · year-over-year · Revenue CAGR 73.7%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | — | -66.0% | -49.9% | +81.8% | -83.0% | +579.3% | +47.6% | +1378.5% | +959.3% | -97.7% |
| Net income growth | — | — | — | — | -1151.6% | — | — | — | — | — |
| EPS growth | — | — | — | — | -1066.7% | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.